ReviewInternational journal of chronic obstructive pulmonary disease2023
Novel Anti-Inflammatory Approaches to COPD.
Review in International journal of chronic obstructive pulmonary disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Efficacy of Biologics in Patients with Moderate to Very Severe COPD: A Systematic Review.International journal of chronic obstructive pulmonary disease · 2026Pooled it
- Therapeutic efficacy and pharmacological mechanism of Bailing capsule on chronic obstructive pulmonary disease: a meta-analysis and network pharmacology.Pharmaceutical biology · 2024Pooled it
- Efficacy and safety of ensifentrine in treatment of COPD: a systematic review and meta-analysis of clinical trials.Therapeutic advances in respiratory diseasePooled it
- Defining disease stability in chronic obstructive pulmonary disease: evidence from phase 3 clinical trials.American journal of respiratory and critical care medicine · 2026Trial
- Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial.Nature aging · 2024Trial
- Article
- Different Inflammatory Phenotypes and Immune Endotypes Drive Disease Heterogeneity in Asthma and COPD.Clinical reviews in allergy & immunology · 2026Review
- Relationship between metabolically unhealthy obesity and chronic obstructive pulmonary disease among U.S. adults: Evidence from NHANES 1999-2018.Clinics (Sao Paulo, Brazil) · 2026Article
- Targeting IL-33 in COPD: mechanistic lessons from clinical trials and the path forward.Respiratory research · 2026Review
- Epithelial cells in chronic obstructive pulmonary disease exacerbations: Targets for lung repair.Pharmacological reviews · 2026Review
- Unknotting the crosstalk between COPD and neuroinflammation.Journal of neuroinflammation · 2026Review
- Nomogram integrating inflammatory biomarkers predicts chronic obstructive pulmonary disease exacerbation Post-Rehabilitation.BMC pulmonary medicine · 2026Article
- Dual role of IL-17A in COPD: amplifier of inflammatory cascades and mediator of airway remodeling and alveolar destruction.Frontiers in immunology · 2026Review
- Biologics for eosinophilic COPD: current applications and future prospects.Frontiers in immunology · 2026Review
- From clinical phenotypes to cellular mechanisms: a precision medicine framework for COPD.Frontiers in immunology · 2026Review
- Design and Implementation of a Multi-Center Trial ofJournal of magnetic resonance imaging : JMRI · 2025Article
- Exosomal MicroRNA let-7 Modulates Lipid Metabolism and Inflammation in Foamy Macrophages of Chronic Obstructive Pulmonary Disease.International journal of molecular sciences · 2025Article
- Review
- Pulmonary Emphysema: Current Understanding of Disease Pathogenesis and Therapeutic Approaches.Biomedicines · 2025Review
- An Animal Model of Liuzijue Based on Kinematic Features Exploration: A Pilot Study Conducting in COPD.Immunity, inflammation and disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Airway inflammation, driven by different types of inflammatory cells and mediators, plays a fundamental role in COPD and its progression. Neutrophils, eosinophils, macrophages, and CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.